We are sorry, the requested page does not exist
Ex-OPEC president Diezani Alison-Madueke charged with bribery
Former OPEC president Diezani Alison-Madueke has been charged with bribery offenses relating to her time as Nigeria's oil minister, the UK National Crime Agency said on Tuesday. Alison-Madueke, 63, has been on bail since first being arrested in London in October 2015. She will appear in court in the British capital on 2 October, the NCA said. Soon after her arrest, her family's lawyer told AFP she would strongly contest corruption allegations that have dogged her during and after her time in former president Goodluck Jonathan's government. Alison-Madueke, in office from 2010 to 2015, was the first woman to be oil minister in Nigeria and the first female president of the global oil cartel OPEC. The head of the NCA's international corruption unit, Andy Kelly, said in a statement: "We suspect Diezani Alison-Madueke abused her power in Nigeria and accepted financial rewards for awarding multi-million-pound contracts." The NCA said Alison-Madueke allegedly benefited from at least £100,000 ($127,000) in cash, chauffeur-driven cars, flights on private jets, luxury holidays for her family, and the use of multiple London properties. The charges also detail financial rewards including furniture, renovation work and staff for the properties, payment of private school fees, and gifts from top designer shops such as Cartier jewelry and Louis Vuitton goods. "Bribery is a pervasive form of corruption, which enables serious criminality and can have devastating consequences for developing countries," Kelly said. "These charges are a milestone in what has been a thorough and complex international investigation," he added. Alison-Madueke has been living in the upmarket St John's Wood area of north London since she was first arrested, and undergone chemotherapy for breast cancer, according to her family. At the time of her arrest, the NCA said only it had detained five people in London on suspicion of international corruption, without naming those held. The Nigerian government of Jonathan's successor Muhammadu Buhari later confirmed Alison-Madueke's arrest and said its law enforcement agencies were cooperating with their British counterparts. Former army general Buhari began an anti-corruption drive after taking office. The NCA said that assets worth millions of pounds in relation to the case have been frozen as part of the investigation. In March, the agency, which targets international and organized crime, provided evidence to the US Department of Justice allowing them to recover assets totaling $53.1 million linked to Alison-Madueke's alleged corruption. The post Ex-OPEC president Diezani Alison-Madueke charged with bribery appeared first on Daily Tribune......»»
Bongbong Marcos sa pagpanaw ni Susan Ople: The Philippines has lost a friend
ISANG malaking kawalan para sa bansa ang pagkamatay ni Department of Migrant Workers Sec. Susan Ople ayon kay Pangulong Bongbong Marcos. Ngayong hapon, August 22, pumanaw si Ople matapos ang pakikipaglaban sa sakit na breast cancer. “It’s a very, very sad news. I have lost a friend. The Philippines has lost a friend,” pagbabahagi ni The post Bongbong Marcos sa pagpanaw ni Susan Ople: The Philippines has lost a friend appeared first on Bandera......»»
Susan Ople ng Department of Migrant Workers pumanaw sa edad na 61
PUMANAW na ang Department of Migrant Workers Secretary Susan Ople ngayong araw, Agosto 22, sa edad na 61 dahil sa breast cancer. Ayon sa inilabas na official statement ng Department of Migrant Workers, pumanaw ito kaninang ala-una ng hapon kasama ang kanyang pamilya. “It is with great sadness that the Department of Migrant Workers announces The post Susan Ople ng Department of Migrant Workers pumanaw sa edad na 61 appeared first on Bandera......»»
‘I have lost a friend’—PBBM on the death of Sec. Toots Ople
President Ferdinand Marcos Jr. on Tuesday expressed his sadness over the passing of Migrant Workers Secretary Susan "Toots" Ople, who died at 61. "I have lost a friend; the Philippines has lost a friend," Marcos told the reporters in a media interview following his visit to Toyota Manufacturing Plant in Laguna. "Secretary Toots was a special person. With the deep compassion really for the people she had to care for, namely the migrant workers, and she was very very—she's a big loss," Marcos added. Ople was a former senator and the daughter of the late labor leader Blas Ople. She was appointed labor secretary by Marcos in May 2022. In his remarks, Marcos said that Ople was "very much following the tradition of Ka Blas Ople, of excellence, of compassion." "It is a great loss for all of us," Marcos said. "It is a great loss to the Philippines for the service we know she could have still rendered." DMW announced Ople's death in a statement, saying: "Secretary Toots peacefully joined our Creator at around 1 PM today, August 22, 2023, surrounded by her family and loved one." While DMW said it would release more details soon, it said on 25 July that Ople underwent a wellness break to mourn and spend time with her family. "Our family lost two good men within a span of five days. They are now in a much better place, free from pain and reunited with our beloved parents and brother, Raul," Ople had said in the DMW's announcement as she went on leave. Ople's passing follows the recent demise of her two brothers, Blas Ople Jr. and Felix "Toti" Ople, who succumbed to lung cancer. Susan Ople, on the other hand, faced breast cancer. Ople has a history of assisting overseas Filipino workers (OFWs) within and outside the government before Marcos Jr. appointed her as a Migrant Workers secretary. She held the position of labor undersecretary in the Gloria Arroyo administration, and she also established and guided the Blas F. Ople Policy and Training Center, a non-governmental organization dedicated to supporting overseas Filipino workers. Furthermore, she is the daughter of Blas Ople, who was the labor secretary under former president Ferdinand E. Marcos Sr. and later took on the role of foreign affairs secretary during the Arroyo administration. The post ‘I have lost a friend’—PBBM on the death of Sec. Toots Ople appeared first on Daily Tribune......»»
AI could halve time reading breast cancer scans, study suggests
Artificial intelligence could help almost halve the workload of radiologists when it comes to searching routine scans for signs of breast cancer, a large Swedish study suggested on Wednesday. The interim results of the trial were hailed as promising, but the authors cautioned that more research was needed before AI can be used to screen for breast cancer on a wider scale. While increasingly convincing chatbots such as ChatGPT have driven speculation about the future potential applications of AI, one area in which the technology has already shown proficiency is in reading medical scans. With many countries suffering from a shortage of radiologists, there are hopes that AI could make the time-consuming job of analyzing routine scans quicker and more accurate. This could have a particularly large impact for breast cancer. More than 2.3 million women were diagnosed with the cancer in 2020 alone, according to the World Health Organization, and it caused 685,000 deaths. Regular screening is vital to identifying early signs of cancer. In Europe, women aged 50 to 69 are advised to get a mammogram every two years, with the resulting scan analyzed by two radiologists. The study in Sweden involved the scans of 80,000 women who had mammograms at four sites in southwest Sweden between April 2021 and July last year. 'Considerable importance' Their scans were randomly divided for analysis to either an AI-supported system or two human radiologists, who served as the control group. The AI algorithm read the scans and predicted the risk of cancer out of 10. Its predictions were then checked by a radiologist. The AI-supported system spotted 20 percent more cancers, the study said, which worked out to be an additional case for every thousand women screened. When it came to false positives -- when a mammogram is first thought to look suspicious but is later cleared -- both the AI-supported system and the two humans spotted the same rate: 1.5 percent. And the workload for radiologists was reduced by 44 percent for the AI group, because only one person was required to read the scans rather than the normal two. "The greatest potential of AI right now is that it could allow radiologists to be less burdened by the excessive amount of reading," said Kristina Lang, a radiologist at Sweden's Lund University and lead author of the study. But Lang said the "promising interim safety results" were "not enough on their own to confirm that AI is ready to be implemented in mammography screening," she said in a statement. It will take two more years before the trial can say whether using AI leads to a reduction in what are called interval cancers, which are detected between routine screenings, the researchers cautioned. Stephen Duffy, a professor of cancer screening at Queen Mary University of London who was not involved in the study, pointed out that the AI algorithm may have over-diagnosed certain forms of early breast cancer called ductal carcinoma in situ. Nonetheless, he praised the "high-quality study", saying that reducing the burden on radiologists' time was "an issue of considerable importance in many breast screening programmes". The post AI could halve time reading breast cancer scans, study suggests appeared first on Daily Tribune......»»
MIT Researchers Develop Innovative Bra for Early Detection of Breast Cancer
Massachusetts Institute of Technology (MIT) researchers have made a groundbreaking discovery in the fight against breast cancer. They have developed a wearable ultrasound device that.....»»
When a growing chest isn’t muscle
Many men do exercises and lift weights to increase the strength and definition of their chest muscles. Enlargement in the area, however, can also be due to enlargement of the breast tissue, a condition called gynecomastia. Most men do not report any symptoms, but sometimes the enlargement can be accompanied by tenderness in the area and sensitivity when rubbing against clothing. [caption id="attachment_160533" align="aligncenter" width="619"] CONSULT your physician to get correct diagnosis.| Photograph courtesy of unsplash/alora griffith[/caption] Most breast lumps in men are usually benign enlargements. This can happen in just one or both breasts, and examination by a physician usually reveals a rubbery, movable lump can be felt just under the nipple area, measuring at least 0.5 cm up to 2.0 cm in diameter. If this lump is not felt on examination, the breast may be made up of mostly fatty tissue (also called pseudogynecomastia or lipomastia, which is due to an increase in breast fat and not breast glandular tissue). If physical examination cannot clearly identify between gynecomastia and pseudogynecomastia, then a breast ultrasound or mammography should be done. While breast cancer occurs primarily in women, it can also occur in men. Male breast cancer makes up less than one percent of all cases of breast cancer, and is usually detected in men between 60 and 70 years of age. Male breast cancers are one-sided, non-tender, firm-to-hard in texture and not movable under the skin. These are also often found off to the side and not under the nipple. There can also be some dimpling in the skin like an orange peel. Certain hormones produce the usual traits seen in males (testosterone) and females (estrogen), but males also produce a small amount of estrogen while females produce a small amount of testosterone. Gynecomastia can occur when men have estrogen levels that are high or out of balance with testosterone levels. Gynecomastia can occur due to natural hormone changes at different times in a male’s life: Infancy. More than half of newborn boys have enlarged breasts because of the estrogen they received from their mothers while developing in the womb. The gynecomastia goes away at two to three weeks after birth. Puberty. Changing hormone levels can cause breast enlargement, but this usually goes away six months to two years after the start of puberty (usually from 12-14 years old). Mid-life and beyond. Men produce less testosterone as they get older. Older men also tend to have more body fat, causing an increase in estrogen. About one in four men between the ages of 50 and 80 have breast enlargement and usually have no symptoms. Men should see a doctor if you have: Breast tissue that is growing very fast A lump bigger than two to three inches under the nipple or a very hard lump that is off to the side of the nipple Pain and tenderness Nipple discharge in one or both breasts A lump on one of your testicles There are some other medical conditions can cause gynecomastia: Obesity Lack of proper nutrition Tumors in the testicles or adrenal glands Liver disease Thyroid disease Lack of testosterone Kidney failure Certain drugs and substances can also cause gynecomastia, including: Steroids Estrogens Treatments for an enlarged prostate or prostate cancer Diuretics (spironolactone) Medications used for heartburn (metoclopramide) Anti-fungal medications Herbal treatments that contain tea tree oil and lavender Excessive alcohol intake Prohibited substances such as amphetamines and marijuana In most cases of gynecomastia, treatment is often not needed. If there is an underlying condition, gynecomastia often goes away after treatment or once any offending medications are stopped. A medication called tamoxifen or anastrazole can also be used for a short while. If the breast enlargement persists despite these, surgery to reduce the size of the breasts can be done. If you suspect you have gynecomastia, consult your physician to get the correct diagnosis and to find the right treatment. The risk for gynecomastia may also be reduced by not using drugs that include anabolic steroids, amphetamines and marijuana, and by avoiding alcohol or drinking in moderation. The post When a growing chest isn’t muscle appeared first on Daily Tribune......»»
Only 1 percent of Pinays are screened for cancer
Screening for breast and cervical cancer among Filipino women could be the lowest in the world with just one percent of eligible women getting themselves screened, the first step to cancer prevention......»»
Acrylamide — Worrisome or not?
Just when we have been forewarned about carbon footprints, transfats, hydrogenated foods, anti-nutrients, nightshades and more, there is acrylamide. The question is, should we all be concerned about it? And if we cannot avoid it, how should we neutralize it somehow? If you take a closer look at the packaging of some processed items (especially from the US), you will find a warning on some product packaging: “This product contains acrylamide and may pose a risk to your health.” The message varies but the intention is the same -- to serve as a warning. In short, buy it at your own risk. While some companies carry the warning, these have been removed since, especially for coffee. Why the fuss? Acrylamide is a chemical that can form in certain foods that are exposed to high temperatures during the cooking process (maillard reaction). It is formed from the sugars and proteins in foods. It is also formed during the process of making paper, dyes and other industrial products. It has been determined that safe consumption of this chemical must not exceed .2mcg daily in order to have no risk of cancer. [Note: The US Toxicology Program has classified acrylamide as “reasonably anticipated to be a human carcinogen.” The US Environmental Protection Agency has classified acrylamide as “likely to be carcinogenic.”] Take heart though, this development is still in the “probable” phase. In trials done on rodents, doses given were 1,000 times higher than the typical human consumption levels from dietary sources. Several meta-analysis and case control studies have been conducted among Japanese men and women in 2018. So far, there has been no link between dietary acrylamide and certain cancers like breast, gynecological and prostate problems, among others. (Reference: foodrevolution.org Ocean Robbins) What is there to eat, one might ask. It has been discovered that foods exposed to high temperatures like potatoes, potato chips, meats and even coffee, toast and prunes, crackers and cookies (would you believe?) contain acrylamide. It has also been found in cigarette smoke. [caption id="attachment_151717" align="aligncenter" width="525"] PHOTOGRAPH COURTESY OF UNSPLASH/eric prouzet | STORE fresh potatoes in room temperature.[/caption] How to avoid it Acrylamide forms when food is exposed above 338 degrees Fahrenheit. Try cooking food lower than this temperature. Reduce the starch content in potatoes by soaking them in water for 15 to 30 minutes and already pre-cut to their final sizes. Store fresh potatoes at room temperature so as to lower their starch content. Flush it out by drinking water. Consume 10 glasses or more daily. Eat raw food. Go on a raw food vegan diet. Or at least increase your raw vegetables and fruit consumption. [caption id="attachment_151718" align="aligncenter" width="525"] PHOTOGRAPH COURTESY OF UNSPLASH/travis jones | INCREASE your vegetable consumption.[/caption] Opt for cooking methods like boiling or steaming instead of frying or roasting. While studies show that there is no definite link between dietary consumption and acrylamide, it pays to be aware and ultimately cautious in the way we cook our food and the food we eat outside of our homes. Affirmation: “My health comes first.” Love and Light. The post Acrylamide — Worrisome or not? appeared first on Daily Tribune......»»
Breast cancer drug shown to reduce recurrence risk
Even when the disease is caught early, breast cancer recurrence is relatively commonplace -- and for survivors, the prospect can be daunting. A drug developed by Swiss pharmaceutical maker Novartis reduced this risk by a quarter in a large group of early-stage survivors of the most common type of breast cancer, according to clinical trial results presented Friday at the American Society of Clinical Oncology's (ASCO) annual meeting, offering patients new hope. The study of ribociclib, which belongs to a newer class of drugs known as molecularly targeted therapies, was described as a "very important and practice-changing clinical trial," by ASCO expert Rita Nanda, who was not involved in the research. The majority of the two million new breast cancers diagnosed globally are in the early phases of disease, defined as stages I through III. "The current standard of therapy for these patients is surgery followed by chemotherapy... or radiation, then followed by between five and 10 years of hormonal blockade by various endocrine therapies," lead author Dennis Slamon of the UCLA Jonsson Comprehensive Cancer Center told reporters. But recurrence is as high as more than one in three people for stage I, and more than one in two in stage III, with the cancer sometimes returning decades later. The clinical trial involved more than 5,100 people with stage II and stage III forms of HR-positive, HER2-negative breast cancer, which is the most common subtype, making up nearly 70 percent of all breast cancer cases in the United States. Half the patients received ribociclib -- marketed under the brand name Kisqali -- as well as hormonal therapy, while the other half received only hormonal therapy. They continued for a treatment period of three years. But the trial was halted early because a significant difference in outcomes between the two groups became apparent, and it would not have been ethical to allow the hormone therapy-only group to miss out on the more effective treatment. Overall, 7.4 percent of patients in the ribociclib group experienced a recurrence against 9.2 percent of patients in the hormone therapy-only group, which means an approximate risk reduction of 25 percent. "Ribociclib also showed more favorable outcomes in overall survival, recurrence-free survival, and distant disease-free survival," a press statement said. While ribociclib, which is already widely approved around the world, has previously shown benefit for people with metastatic breast cancer, the new study was able to demonstrate it also improves outcomes for people with earlier stages, including those with cancer that hasn't yet spread to the lymph nodes. The most common side effects were abnormally low counts of a type of white blood cell called neutrophils, as well as joint pain. Less common effects included gastrointestinal issues and fatigue. Ribociclib works by disrupting proteins in breast cancer cells responsible for cell division. Novartis plans to continue to study longer-term outcomes. ia/caw © Agence France-Presse Add to cart Print Download Share this document Copy the content The post Breast cancer drug shown to reduce recurrence risk appeared first on Daily Tribune......»»
Muntinlupa provides free early detection tests for breast cancer
The Muntinlupa city government inked on 22 May a memorandum of agreement with the Medical Center Muntinlupa Inc. to provide free breast ultrasound as well as mammography tests to aid in the early detection of breast cancer among Muntinlupeños. "We definitely welcome this development as this enables the city government to address the problem of breast cancer head-on," Mayor Ruffy Biazon said. "By early detection, we hope to save many families from the heartbreak of losing mothers and women family members to an otherwise preventable disease. “ Under the MoA, the city government will shoulder the cost of the tests of patients and target beneficiaries identified by its Kalingang Munti Action Center and verified by the Gender and Development Office through their respective processes. The city's Sangguniang Panlungsod provided the legal basis for the MoA, recently approving Resolution 2023-238 that allowed Biazon to represent the city government in the signed agreement. The MCM was represented by board chairman Ning I. Singh and management consultant Uriel S. Halum. According to the International Agency for Research on Cancer, one out of 13 Filipina women are more likely to develop breast cancer in their lifetime, making them significantly under high risk. Similarly, the Global Cancer Report, which surveyed 15 Asian countries, showed that the Philippines has the highest breast cancer mortality rate among its counterparts. Studies and expert recommendations have shown that higher survival rates are possible through early detection tests such as breast ultrasound and mammography. However, these procedures are prohibitively expensive for low-income countries, making access to these tests highly critical for any strategy aiming to tackle the problem of breast cancer. "We believe (by making these tests more accessible), we can change that," Biazon said. The post Muntinlupa provides free early detection tests for breast cancer appeared first on Daily Tribune......»»
140,000 benefit from Taguig’s breast cancer program
Over 140,000 patients received assistance from the Taguig City government in its community-based early breast cancer detection program, according to Mayor Lani Cayetano......»»
Mammograms should start at 40, says US task force
All women should get mammogram screening for breast cancer starting from age 40, rather than 50, an influential US health body announced Tuesday, a move it said could save thousands of lives. Breast cancer is the second most common cancer and the second most common cause of cancer death for women in the United States, killing around 42,000 women and 500 men, according to official data. Black women are 40 percent more likely to die than white women. The Preventive Services Task Force, a group of independent experts appointed by the Department of Health and Human Services, said that while it previously recommended women in their 40s make individual choices about when to start screening, the new guidance could result in 19 percent more lives being saved. "New and more inclusive science about breast cancer in people younger than 50 has enabled us to expand our prior recommendation and encourage all women to get screened every other year starting at age 40," said the Task Force in a statement. Based on the evidence, the new recommendation was assigned a "Grade B" rating, its second-highest level. The guidance is still considered a draft, with the Task Force posting the evidence it considered on its website and allowing time for public comments and review. American health insurance is required to cover any service USPSTF recommends, regardless of cost. "Ensuring Black women start screening at age 40 is an important first step, yet it is not enough to improve the health inequities we face related to breast cancer," added Task Force vice chair Wanda Nicholson. "In our draft recommendation, we underscore the importance of equitable follow-up after screening and timely and effective treatment of breast cancer and are urgently calling for more research on how to improve the health of Black women." The draft recommendation applies to women at "average risk" of breast cancer, which includes people with a family history of breast cancer or other risk factors such as having dense breasts, which about half of all women do. It doesn't apply to people who have a prior history of breast cancer, who have certain genetic markers that place them at high risk, who have had high-dose radiation therapy from a young age or had high-risk lesions taken on biopsies. The body said there was lingering uncertainty when it came to the benefits and harms of screening people aged 75 and older. "The balance of benefits and harms may shift as women age, but there is very limited research on this age population," it said in a statement. The Task Force said more research was needed to determine whether women with dense breasts should have additional screening with ultrasound or MRI, since mammograms may not work as well for them. Annual screening Sarah Friedewald, chief of breast imaging at Northwestern Medicine, told AFP that while she applauded the Task Force for recognizing age 50 was too late to start screening, "We feel very strongly that it should be every year." "If you increase the interval between the screens, you just allow the cancers to grow larger and potentially less treatable," she said, adding her recommendation was backed by numerous clinical trials and modeling data. When tumors are caught early, they can be surgically removed, without resorting to breast removal. The main risks linked to mammograms, and X-ray pictures of the chest, are anxieties associated with patients getting called back for additional imaging and biopsies that often turn out to be benign. The radiation risk associated with mammography is minimal. The post Mammograms should start at 40, says US task force appeared first on Daily Tribune......»»
Novartis NATALEE trial meets primary endpoint
Novartis announced positive topline results from an interim analysis of NATALEE, a Phase III trial evaluating ribociclib plus endocrine therapy in a broad population of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2) early breast cancer at risk of recurrence. The Independent Data Monitoring Committee recommended stopping the trial early as the primary endpoint of invasive disease-free survival has been met as ribociclib plus ET significantly reduced the risk of disease recurrence, compared to standard adjuvant ET alone, with consistent benefit in patients with stage II and stage III EBC regardless of nodal involvement. “While most patients are diagnosed and treated early with the aim to cure breast cancer, the risk of cancer returning, often as metastatic disease, peaks within three years after diagnosis, but never goes away completely,” said Dennis J. Slamon, MD, director of Clinical/Translational Research, University of California, Los Angeles Jonsson Comprehensive Cancer Center and Chairman and Executive Director of Translational Research In Oncology and NATALEE trial lead investigator. "There is a critical need for new, well-tolerated options that keep patients cancer-free without disrupting quality of life. The NATALEE trial, where ribociclib was given for three years plus ET, was designed with these unmet needs in mind, and it is extremely encouraging that this study met its primary endpoint,” he added. Per the NATALEE study protocol, patient follow-up will continue to evaluate long-term outcomes, including overall survival. "The positive topline results from NATALEE represent a major milestone in our ambition to expand the benefits of ribociclib to patients with earlier stages of breast cancer, building on the heritage of this effective treatment in HR+/HER2- metastatic breast cancer,” said Shreeram Aradhye, M.D., president of Global Drug Development and chief medical officer of Novartis. “These data have the potential to be paradigm-shifting for patients at risk of recurrence, including those with no nodal involvement, who have limited well-tolerated options to prevent recurrence. Our teams are working on submissions to health authorities around the world with the hope to bring ribociclib to many more patients diagnosed with breast cancer.” “The result of the NATALEE trial is a welcome development in the management of breast cancer, offering new hope for a longer life in a broad population of patients with stage II and III HR-positive/HER2-negative early breast cancer at risk of recurrence,” said Dr. Rosario V. Pitargue, the president of Philippine Society of Medical Oncology. “These findings build on the legacy of ribociclib in metastatic breast cancer (MBC). Ribociclib is the first and only CDK4/6 inhibitor so far to have shown both consistent and significant improvements in overall survival across 3 phase III trials,” said Novartis Healthcare Philippines country president Joel Chong. NATALEE is a global Phase III multi-center, randomized, open-label trial to evaluate the efficacy and safety of ribociclib with ET as adjuvant treatment versus ET alone in patients with HR+/HER2- EBC, being conducted in collaboration with Translational Research In Oncology. The primary endpoint of NATALEE is iDFS as defined by the Standardized Definitions for Efficacy End Points criteria; secondary endpoints include safety, quality of life, and overall survival, among others. iDFS is a composite endpoint in EBC adjuvant trials, which incorporates locoregional relapse, ipsilateral and contralateral invasive breast cancer, distant recurrence, and types of new cancer events or death from any cause. Approximately 5,100 adult patients with HR+/HER2- EBC across 20 countries were randomized in the trial, including patients with tumor stages IIA (select patients), IIB or III, regardless of nodal involvement. NATALEE explored a lower starting dose (400 mg) of ribociclib than the dose approved for treatment in MBC (600 mg) with the goal to minimize disruptions to patient quality of life without compromising efficacy. Ribociclib, on the other hand, has consistently demonstrated overall survival benefit while preserving or improving quality of life across three Phase III trials. Updates to the NCCN Guidelines® for breast cancer, released in January 2023, recommend ribociclib as the only Category 1 preferred CDK4/6 inhibitor for first-line treatment of patients with HR+/HER2- MBC when combined with an AI. Additionally, ribociclib has the highest rating of any CDK4/6 inhibitor on the ESMO Magnitude of Clinical Benefit Scale, achieving a score of five out of five for first-line premenopausal patients with HR+/HER2- advanced breast cancer. Ribociclib, in combination with either letrozole or fulvestrant has uniquely, among other CDK4/6 inhibitors, received a score of four out of five for postmenopausal patients with HR+/HER2- advanced breast cancer treated in the first line. The post Novartis NATALEE trial meets primary endpoint appeared first on Daily Tribune......»»
Mental health inclusion to PhilHealth eyed
Senator Mark Villar on Wednesday has filed a measure seeking to expand the country’s health insurance program for about 3.6 million Filipino patients with psychiatric disorder. The lawmaker filed the Senate Bill 2062 or an Act Expanding Philippine Health Insurance Coverage, granting also a benefit package to all mental health patients in the country. “We should not set aside mental health disorders, it’s affecting a lot of Filipinos. In fact, according to the Department of Health there are around 3.6 million Filipinos facing mental health issues,” Villar said in a statement. Citing the recently published study by the Harvard Humanitarian Initiative Resilient Communities Program, Villar underscored the “costly treatments and services” that usually barred patients to access proper mental health care treatment in the Philippines. The measure is set to provide benefit packages to those with mental disabilities covering emergency services, psychiatric and neurological services, as well as mental health gap action program. “We are pushing for a benefit package so that our fellow countrymen will no longer thing about the treatment cost,” he said, noting that mental health patients are likewise entitled to gain support from the government. Under the bill, non-member parents of minors suffering from mental health disorders are also allowed to avail of the treatment package from the PhilHealth. “Mental health is equally important as physical health. It is a fundamental aspect of our overall well-being. We filed this bill to normalize seeking help for mental health disorders and to break the stigma that comes with it. By recognizing and prioritizing mental health, we can create a healthier, happier, and more inclusive society for Filipinos, especially the youth,” Villar said. Currently, PhilHealth is offering inpatient benefits being paid to the accredited Health Care institution; as well as outpatient benefits with day surgeries, radiotheraphy, hemodialysis and blood transfusion. Under the PhilHealth Z benefits program, those 20 listed illness and health conditions including the Acute lymphocytic leukemia, Early breast cancer, prostate cancer, kidney transplant, standard risk coronary bypass graft, tetralogy of Fallot, ventricular septal defect, cervical cancer, Z MORPH (Mobility, Orthosis, Rehabilitation and Prosthesis Help), selected orthopedic implants, peritoneal dialysis, colon cancer, rectal cancer, expanded mobility orthosis rehabilitation help, premature and small newborns, children with developmental disabilities, children with mobility impairment, children with visual impairment, children with hearing impairment and rheumatic heart disease. PhilHealth also covers benefits for outpatient malaria package, HIV-AIDS package, anti-tuberculosis treatment through directly-observed treatment Short-course, voluntary Surgical Contraception Procedures and animal bite treatment Package. The post Mental health inclusion to PhilHealth eyed appeared first on Daily Tribune......»»
Even teenage girls can have breast cancer – experts
Even teenage girls can suffer from breast cancer, experts warned yesterday as they stressed the importance of early screening for the most common cancer among Filipino women......»»
Gigi de Lana nagpagupit ng buhok para sa inang may stage 4 breast cancer: ‘Gusto ko po halos parehas kami ng iksi ng hair’
MALALIM pala ang dahilan kung bakit nagpagupit ng buhok ang Kapamilya singer-actress na si Gigi de Lana. Iba’t iba ang reaksyon na nabasa namin mula sa mga netizens nang makita nila ang short hair ni Gigi – may na-impress at nagandahan sa bago niyang hairstyle pero meron ding kumontra at nangnega. Sa unang pagkakataon ay […] The post Gigi de Lana nagpagupit ng buhok para sa inang may stage 4 breast cancer: ‘Gusto ko po halos parehas kami ng iksi ng hair’ appeared first on Bandera......»»
Globe Platinum raises P450,000 for underprivileged breast cancer patients
One of the event’s highlights was “Monster in Pink,” a commissioned piece by renowned street artist Distort Monsters, an ambassador of Globe Platinum......»»
Cebu Pink Paddlers bag silver in Malaysia competition
CEBU CITY, Philippines—The Cebu Pink Paddlers Dragon Boat Team won a silver medal in the Sarawak International Dragon Boat Regatta held in Kuching, Malaysia over the weekend. The Pink Paddlers, comprised of breast cancer survivors, earned a silver in the cancer survivors category of the international race. The gold medal went to Team DNA of […] The post Cebu Pink Paddlers bag silver in Malaysia competition appeared first on Cebu Daily News......»»
Badjao Girl Rita Gaviola walang breast cancer: Hindi na ako magwo-worry, matututukan ko na ang baby ko
NAKAHINGA na nang maluwag ang dating “Pinoy Big Brother” housemate na si Rita Gaviola nang makuha ang resulta ng kanyang medical check-up kamakailan. Feeling relieved ang internet sensation nang sabihin ng doktor sa kanya na wala siyang breast cancer at cleared na rin ang suspected cyst na nakapa noon sa dibdib niya. Sumailalim sa medical […] The post Badjao Girl Rita Gaviola walang breast cancer: Hindi na ako magwo-worry, matututukan ko na ang baby ko appeared first on Bandera......»»